aod9604 uses AOD 9604 Peptide AOD 9604 5MG - NuRev

Treatment with intranasal cyanocobalamin should be delayed until symptoms resolve in patients with nasal congestion, allergic rhinitis, and upper respiratory infection

The absence of specific warnings does not mean a medicine is safe for all users

Malabsorption issues (e.g., digestive disorders like Crohns or celiac disease)

But what does that really mean

This regulatory history is worth understanding for context: the compound has more human safety and pharmacokinetic data behind it than many newer research peptides, but the pivotal efficacy trial ultimately did not succeed, which is why AOD9604 never reached the market as an approved obesity drug

Additionally, a decrease of fat mass was shown, but not of lean mass (183)